{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:46:11Z","timestamp":1787312771861,"version":"build-2736575974"},"reference-count":33,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Global Health and Vaccination Research (GLOBVAC) Programme of the Medical Research Council of Norway"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2021,10,31]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Selection for resistance to azithromycin (AZM) and other antibiotics such as tetracyclines and lincosamides remains a concern with long-term AZM use for treatment of chronic lung diseases (CLD). We investigated the impact of 48\u2005weeks of AZM on the carriage and antibiotic resistance of common respiratory bacteria among children with HIV-associated CLD.<\/jats:p>\n                  <jats:p>\n                    Nasopharyngeal (NP) swabs and sputa were collected at baseline, 48 and 72\u2005weeks from participants with HIV-associated CLD randomised to receive weekly AZM or placebo for 48\u2005weeks and followed post-intervention until 72\u2005weeks. The primary outcomes were prevalence and antibiotic resistance of\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    (SP),\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    (SA),\n                    <jats:italic>Haemophilus influenzae<\/jats:italic>\n                    (HI) and\n                    <jats:italic>Moraxella catarrhalis<\/jats:italic>\n                    (MC) at these timepoints. Mixed-effects logistic regression and Fisher's exact test were used to compare carriage and resistance, respectively.\n                  <\/jats:p>\n                  <jats:p>\n                    Of 347 (174 AZM, 173 placebo) participants (median age 15\u2005years (IQR 13\u201318), female 49%), NP carriage was significantly lower in the AZM (n=159) compared to placebo (n=153) arm for SP (18%\n                    <jats:italic>versus<\/jats:italic>\n                    41%,\n                    <jats:italic>p<\/jats:italic>\n                    &lt;0.001), HI (7%\n                    <jats:italic>versus<\/jats:italic>\n                    16%, p=0.01) and MC (4%\n                    <jats:italic>versus<\/jats:italic>\n                    11%, p=0.02); SP resistance to AZM (62% (18 out of 29)\n                    <jats:italic>versus<\/jats:italic>\n                    13% (8 out of 63),\n                    <jats:italic>p<\/jats:italic>\n                    &lt;0.0001) or tetracycline (60% (18 out of 29)\n                    <jats:italic>versus<\/jats:italic>\n                    21% (13 out of 63),\n                    <jats:italic>p<\/jats:italic>\n                    &lt;0.0001) was higher in the AZM arm. Carriage of SA resistant to AZM (91% (31 out of 34)\n                    <jats:italic>versus<\/jats:italic>\n                    3% (1 out of 31),\n                    <jats:italic>p<\/jats:italic>\n                    &lt;0.0001), tetracycline (35% (12 out of 34)\n                    <jats:italic>versus<\/jats:italic>\n                    13% (4 out of 31), p=0.05) and clindamycin (79% (27 out of 34)\n                    <jats:italic>versus<\/jats:italic>\n                    3% (1 out of 31),\n                    <jats:italic>p<\/jats:italic>\n                    &lt;0.0001) was also significantly higher in the AZM arm and persisted at 72\u2005weeks. Similar findings were observed for sputa.\n                  <\/jats:p>\n                  <jats:p>The persistence of antibiotic resistance and its clinical relevance for future infectious episodes requiring treatment needs further investigation.<\/jats:p>","DOI":"10.1183\/23120541.00491-2021","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T11:05:31Z","timestamp":1637233531000},"page":"00491-2021","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease"],"prefix":"10.1183","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9483-3051","authenticated-orcid":false,"given":"Regina E.","family":"Abotsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4897-458X","authenticated-orcid":false,"given":"Victoria","family":"Simms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9967-5822","authenticated-orcid":false,"given":"Andrea M.","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine","family":"Barthus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucky G.","family":"Ngwira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Kwambana-Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Heyderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon \u00d8.","family":"Odland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashida A.","family":"Ferrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix S.","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"2024101711250698000_8.1.00491-2021.1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl014"},{"key":"2024101711250698000_8.1.00491-2021.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-015-2480-0"},{"key":"2024101711250698000_8.1.00491-2021.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104623"},{"key":"2024101711250698000_8.1.00491-2021.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201809-1739OC"},{"key":"2024101711250698000_8.1.00491-2021.5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","article-title":"Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases","volume":"1","author":"Serisier","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2024101711250698000_8.1.00491-2021.6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02067-13"},{"key":"2024101711250698000_8.1.00491-2021.7","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202698"},{"key":"2024101711250698000_8.1.00491-2021.8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis271"},{"key":"2024101711250698000_8.1.00491-2021.9","doi-asserted-by":"crossref","first-page":"e2028484","DOI":"10.1001\/jamanetworkopen.2020.28484","article-title":"Effect of once-weekly Azithromycin vs placebo in children with HIV-associated chronic lung disease: the BREATHE randomized clinical trial","volume":"3","author":"Ferrand","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2024101711250698000_8.1.00491-2021.10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12879-021-05904-3","article-title":"Prevalence and antimicrobial resistance profiles of respiratory microbial flora in African children with HIV-associated chronic lung disease","volume":"21","author":"Abotsi","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2024101711250698000_8.1.00491-2021.11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12866-017-0982-x","article-title":"Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control","volume":"17","author":"Bojang","year":"2017","journal-title":"BMC Microbiol"},{"key":"2024101711250698000_8.1.00491-2021.12","unstructured":"CLSI . Performance Standards for Antimicrobial Susceptibility Testing. 28th Edn. Wayne, PA, Clinical Laboratory Standards Institute, 2018."},{"key":"2024101711250698000_8.1.00491-2021.13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.conctc.2018.03.008","article-title":"Different ways to estimate treatment effects in randomised controlled trials","volume":"10","author":"Twisk","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"key":"2024101711250698000_8.1.00491-2021.14","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000247109.44249.ac"},{"key":"2024101711250698000_8.1.00491-2021.15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1440-1843.2012.02135.x","article-title":"Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects","volume":"17","author":"Hodge","year":"2012","journal-title":"Respirol Carlton Vic"},{"key":"2024101711250698000_8.1.00491-2021.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15786-9"},{"key":"2024101711250698000_8.1.00491-2021.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2008.09.001"},{"key":"2024101711250698000_8.1.00491-2021.18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1371\/journal.pmed.1000377","article-title":"Antibiotic selection pressure and macrolide resistance in Nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial","volume":"7","author":"Skalet","year":"2010","journal-title":"PLoS Med"},{"key":"2024101711250698000_8.1.00491-2021.19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu552"},{"key":"2024101711250698000_8.1.00491-2021.20","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.3.356"},{"key":"2024101711250698000_8.1.00491-2021.21","doi-asserted-by":"publisher","DOI":"10.1086\/655697"},{"key":"2024101711250698000_8.1.00491-2021.22","doi-asserted-by":"publisher","DOI":"10.1086\/322656"},{"key":"2024101711250698000_8.1.00491-2021.23","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00026"},{"key":"2024101711250698000_8.1.00491-2021.24","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp256"},{"key":"2024101711250698000_8.1.00491-2021.25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fcimb.2016.00098","article-title":"Macrolide resistance in Streptococcus pneumoniae","volume":"6","author":"Schroeder","year":"2016","journal-title":"Front Cell Infect Microbiol"},{"key":"2024101711250698000_8.1.00491-2021.26","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.4.6.973"},{"key":"2024101711250698000_8.1.00491-2021.27","doi-asserted-by":"publisher","DOI":"10.1086\/380126"},{"key":"2024101711250698000_8.1.00491-2021.28","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3201\/eid1106.050147","article-title":"Hidden epidemic of macrolide-resistant pneumococci","volume":"11","author":"Klugman","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"2024101711250698000_8.1.00491-2021.29","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm235"},{"key":"2024101711250698000_8.1.00491-2021.30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00194-2020"},{"key":"2024101711250698000_8.1.00491-2021.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1937"},{"key":"2024101711250698000_8.1.00491-2021.32","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00035-14"},{"key":"2024101711250698000_8.1.00491-2021.33","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00518.2016"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00491-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:13:06Z","timestamp":1740355986000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00491-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,7]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1183\/23120541.00491-2021"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00491-2021","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}